163 related articles for article (PubMed ID: 30146168)
1. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.
Matthew AN; Leidner F; Newton A; Petropoulos CJ; Huang W; Ali A; KurtYilmaz N; Schiffer CA
Structure; 2018 Oct; 26(10):1360-1372.e5. PubMed ID: 30146168
[TBL] [Abstract][Full Text] [Related]
2. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
[TBL] [Abstract][Full Text] [Related]
3. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
Guo Z; Black S; Hu Y; McMonagle P; Ingravallo P; Chase R; Curry S; Asante-Appiah E
J Biol Chem; 2017 Apr; 292(15):6202-6212. PubMed ID: 28228479
[TBL] [Abstract][Full Text] [Related]
4. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
[TBL] [Abstract][Full Text] [Related]
6. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
7. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
Xue W; Wang M; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.
Matthew AN; Zephyr J; Hill CJ; Jahangir M; Newton A; Petropoulos CJ; Huang W; Kurt-Yilmaz N; Schiffer CA; Ali A
J Med Chem; 2017 Jul; 60(13):5699-5716. PubMed ID: 28594175
[TBL] [Abstract][Full Text] [Related]
10. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
11. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.
Jensen SB; Serre SB; Humes DG; Ramirez S; Li YP; Bukh J; Gottwein JM
Antimicrob Agents Chemother; 2015 Dec; 59(12):7426-36. PubMed ID: 26392503
[TBL] [Abstract][Full Text] [Related]
12. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
[TBL] [Abstract][Full Text] [Related]
13. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.
Soumana DI; Kurt Yilmaz N; Ali A; Prachanronarong KL; Schiffer CA
J Am Chem Soc; 2016 Sep; 138(36):11850-9. PubMed ID: 27512818
[TBL] [Abstract][Full Text] [Related]
15. Computational study on the inhibitor binding mode and allosteric regulation mechanism in hepatitis C virus NS3/4A protein.
Xue W; Yang Y; Wang X; Liu H; Yao X
PLoS One; 2014; 9(2):e87077. PubMed ID: 24586263
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
Xue W; Pan D; Yang Y; Liu H; Yao X
Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
[TBL] [Abstract][Full Text] [Related]
18. Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study.
Pan D; Xue W; Zhang W; Liu H; Yao X
Biochim Biophys Acta; 2012 Oct; 1820(10):1526-34. PubMed ID: 22698669
[TBL] [Abstract][Full Text] [Related]
19. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors.
Özen A; Prachanronarong K; Matthew AN; Soumana DI; Schiffer CA
Crit Rev Biochem Mol Biol; 2019 Feb; 54(1):11-26. PubMed ID: 30821513
[TBL] [Abstract][Full Text] [Related]
20. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
